Search
Vosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development
Acetylcholine
go.drugbank.com/drugs/DB03128ApprovedInvestigationalIt is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.
Products: Miogan Pws 20mg/vialrCFP-10
go.drugbank.com/drugs/DB21907ApprovedrCFP-10 is a recombinant culture filtrate protein of Mycobacterium tuberculosis used as an ingredient in the diagnostic agent SIILTIBCY along with rdESAT-6.
Isosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalIt was approved by the FDA in 1980, but has since been discontinued.
Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962.
Bromothalonil
go.drugbank.com/drugs/DB14199ApprovedIn 2005, MDBGN was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].
Pagoclone
go.drugbank.com/drugs/DB04903InvestigationalIt is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures
Clarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit.
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalA compound formed in the liver from ammonia produced by the deamination of amino acids.
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer